Apr 29 |
Why Clever Leaves Holdings Shares Are Trading Lower By Around 60%? Here Are Other Stocks Moving In Monday's Mid-Day Session
|
Apr 11 |
Kyverna Therapeutics to attend the 2024 American Academy of Neurology (AAN) Annual Meeting in Denver, CO, With Data on KYV-101 in the Treatment of Patients with Neurological Autoimmune Diseases
|
Mar 29 |
First-in-Disease Use of Kyverna Therapeutics' KYV-101 in Patients With Progressive Multiple Sclerosis Published in Med
|
Mar 26 |
Kyverna Therapeutics Provides Business Update and Reports Full Year 2023 Financial Results
|
Mar 14 |
Why That Hot Biotech IPO Could Be a Winner
|
Mar 8 |
Kyverna Therapeutics and Stanford University Agree to Evaluate KYV-101 in Patients with Non-Relapsing and Progressive Forms of Multiple Sclerosis
|
Mar 7 |
How Kyverna is positioned for success on autoimmune therapy: CEO
|
Feb 12 |
Kyverna Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares
|
Feb 12 |
IPO Roundup: Wetouch Technology, Amphitrite Digital, and more
|
Feb 8 |
Kyverna Therapeutics stock rallies 59% following $319M IPO
|